A proposed detection technology does not establish analytical reliability in an individual investigation.
The supplied mini-review discussed drug-facilitated crime, specimen timing, established analytical challenges and emerging sensors or computational approaches. It emphasized that metabolism and delayed sampling can complicate detection and discussed future technology as a possible response.
The publication was a narrative synthesis, not a new validation study. It did not provide case-specific sensitivity, selectivity or error rates for every proposed device. Benzodiazepines also differ in disposition, so a general statement about rapid breakdown cannot define one universal detection window.
For an evidentiary assessment, obtain the actual laboratory method, analyte coverage, specimen, collection time and validation data. Separate research proposals from deployed validated testing. A negative result and an uncorroborated technological promise each require more context before either can resolve an exposure allegation.
Source: Publication PMC12507772. The case-review applications above are interpretive analysis.
Related reading: Remimazolam and Malignant-Hyperthermia Mutations: A Cell Assay Is Not a Patient Safety Trial.